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Abstract A 20-yr-old man with Proteus syndrome (PS) and somatic mosaicism of the AKT1
c.49G>A p.(E17K) variant had asymmetric overgrowth of the right frontal and facial bones,
asymmetric spinal overgrowth with thoracolumbar scoliosis, dilatation of the inferior vena
cava, testicular cystadenoma, bilateral knee deformities, macrodactyly, and apparent intel-
lectual disability. Miransertib (ARQ 092) is an oral, allosteric, selective pan-AKT inhibitor ini-
tially developed for cancer therapeutics, now being evaluated for the treatment of PS. After
baseline evaluation, the patient started unblinded treatment of 10 mg oral miransertib daily
(∼5 mg/m2/day), escalated to 30 mg daily (∼15 mg/m2/day), and then to 50 mg daily
(∼25mg/m2/day) after 3 mo of treatment. Adverse events included dry mouth, one episode
of gingivostomatitis, and loose, painful dentition due to preexisting periodontal disease, all
of which resolved spontaneously. After 11 mo of treatment, the patient reported improved
general well-being, increasedmobility of the ankle, spine, and hands, a subjective decrease
in size of the right facial bone overgrowth, and reduced areas of cerebriform connective tis-
sue nevi on the soles. Whole-body MRI findings were stable without apparent disease pro-
gression. We conclude that 1 yr of treatment with miransertib was beneficial in this case.
[Supplemental material is available for this article.]
INTRODUCTION
Patients with Proteus syndrome (PS) have severe, progressive overgrowth that can affect
nearly any region of the body (Biesecker 2006). It is progressive and causes death (Sapp
et al. 2017), either by distortion or compression of vital structures by overgrown tissues,
thromboembolism (Keppler-Noreuil et al. 2017), respiratory disease associated with pulmo-
nary cysts (Newman et al. 1994; Lim et al. 2011), or malignant transformation in an over-
grown tissue such as a parotid tumor, ovarian cystadenoma, or testicular tumor (Cohen
2005). Common syndromic manifestations include large superficial or deep lipomatous
overgrowths, intellectual disability, seizures and other neurological problems, and severe
skeletal deformities with skull overgrowth, kyphoscoliosis, asymmetric macrodactyly and
valgus, or varus deformities of the knees. The cerebriform connective tissue nevus
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(CCTN) of the soles found in many patients is a specific, but not pathognomonic finding. It
makes weight-bearing and footwear uncomfortable, and hygiene is difficult to maintain
(Cohen 2014).
A somatic variant in the AKT1 gene—c.49G>A, p.Glu17Lys—is the only reported cause
of PS (Lindhurst et al. 2011). AKT1 is a serine-threonine kinase that participates in the AKT/
PI3K/mTOR pathway: The p.Glu17Lys variant constitutively activates the protein, limiting
apoptosis and promoting growth, among other effects (Carpten et al. 2007). Miransertib
(ARQ 092) is an oral, allosteric, selective pan-AKT inhibitor that inhibits both active and in-
active forms of AKT. In in vitro and in vivo experiments, it demonstrated antiproliferative
activity in cancer and in cells derived from patients with PIK3CA-related overgrowth syn-
drome (PROS) and PS (Lindhurst et al. 2015; Yu et al. 2015). An abstract describing patients
with ovarian cancers bearing PIK3CA or AKT1 variants treated with miransertib reported fa-
vorable efficacy and side effects (Hyman et al. 2018). More recently, metastatic tumors and
some skeletal deformities improved after 22 mo of treatment of a teenager with PS and
metastatic ovarian cancer (Leoni et al. 2019). The only available alternative treatments of
PS are palliative. Presently, 29 participants with either PS or PROS have been treated
with miransertib in two ongoing research projects and under compassionate use programs
(B Schwartz, unpubl. data). Six of these individuals, all with PS, were treated with miransertib
in a research project being run by the U.S. National Institutes of Health (NIH) (Keppler-
Noreuil et al. 2019). That study reached a pharmacodynamic endpoint of 50% inhibition
of AKT in five of six treated patients and suggestions of efficacy for CCTN reduction and
pain reduction, although these were secondary endpoints not evaluated for statistical sig-
nificance. Based on these suggestions of efficacy and apparently tolerable adverse effects,
we treated a young man with PS with miransertib on a compassionate use basis and report
that experience here.
RESULTS
Clinical Presentation and Family History
The patient was born at 41 wk gestation by vaginal delivery weighing 3.6 kg with no prenatal
complications. Both parents had learning difficulties; otherwise there was no relevant family
history. His medical history was complicated by nonaccidental fractures of the femur, tibia,
and clavicle at age 5 wk and carewas assumed by the Public Guardian. His current foster par-
ents brought him to genetics at age 16 mo with global developmental delay, overgrowth of
the right frontal bone, and macrodactyly of the right middle finger. A clinical diagnosis of PS
was based on the developmental delay, macrodactyly, and frontal overgrowth (Biesecker
et al. 1999). Subsequent developments are listed in Table 1.
The Guardianship Board of the New South Wales Civil and Administrative Tribunal gave
informed consent to applications by the patient and his foster parents for compassionate use
of miransertib. This was approved by the Therapeutic Goods Administration, Australia, and
the Quality Use of Medicines Committee of the John Hunter Hospital. After an initial dose
of 10 mg daily the dose was increased after 1 mo to 30 mg per day and one month later
to 50 mg per day (∼25 mg/m2).
Genomic Analysis
Amosaic c.49G>A variant in AKT1was identified on Sanger sequencing of DNA from fibro-
blasts cultured from an affected area of skin (Table 2). Blood was not tested for this variant as
the underlying variant is not usually found in blood (Lindhurst et al. 2011), and DNA from af-
fected tissue was available.
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Treatment Outcomes and Adverse Effects
The patient and his family reported that dryness of the mouth appeared soon after starting
treatment, and this persisted unchanged. An episode of gingivostomatitis was treated with
local analgesics. No previous similar lesions could be recalled. His pediatric dentist attribut-
ed loose painful dentition, noted after 3 mo treatment at the 25 mg/m2/day dose and
Table 1. Clinical timeline
Age (yr) Clinical details
2 Left convergent strabismus
Clinically diagnosed lipomatous overgrowths of the right anterior abdominal wall, right axilla,
and chin, with significant cosmetic deformity
Overgrowth of right leg requiring osteotomy with stapling of the distal femoral growth plate at
age 31 mo
Amputation of overgrown left second and third toes
3 Amputation of right third toe
Cerebriform connective tissue nevus of the soles
Vineland Adaptive Behavior Scales, Interview Edition, standardized with mean 100, 95%
confidence interval ± 15, assessed at age 41 mo (Supplement 1) was 61±6 (0.5th centile)
4 Valgus deformity of right knee and varus deformity of the left knee
Varicose veins of right leg and continued growth of amputated toe stumps
Griffiths assessment at age 58 mo indicated 36 mo attainment
5 Attention deficit hyperactivity disorder treated with methylphenidate.
6 Factor V Leiden detected at National Institutes of Health on screening for thrombophilia,
performed because of thromboembolism reported in other affected patients
Verbal IQ was 57 and performance IQ was 65 on WISC-IV
7 Asymmetric testicular growth
11 Superficial thrombophlebitis of varicose veins in the right leg
15 Progressive valgus deformity of one knee and varus deformity of the other were treated
successfully with bilateral epiphyseal stapling that enabled the patient to continue activities
like walking and riding a bicycle
17 Excision of benign right epididymal cystadenoma; another epididymal lump on that side has
not grown and is being observed
Thrombosis of superficial varicose veins in the right leg at age 17 yr has been managed with
clodipogrel and perioperative prophylaxis with enoxaparin sodium
20 Repeated surgery to the turbinate bones and sinuses was planned for progressive overgrowth
of the right frontal lesion, which was obstructing the right superomedial visual field, the
nasal passages, and frontal sinus
Weight 60 kg, height 201 cm (>97th centile), head circumference 59 cm (>97th centile)
Middle finger lengths were right 11 cm (>>97th centile) and left 8.3 cm (∼75th centile),
midhand lengths were right 23 cm (>97th centile) and left 19 cm (∼60th centile); the right
foot measured 26.5 cm (50th–75th centile), left 29 cm (>97th centile); and upper to lower
segment ratio was 0.94 and the arm span was 185 cm
Blood pressure 116/58
Table 2. Variant table
Gene Chromosome
HGVS DNA
reference
HGVS protein
reference
Variant type
(substitution,
deletion, etc.)
Predicted
effect
dbSNP/
dbVar ID
Genotype
(heterozygous/
homozygous) ClinVar ID
AKT1 14 NM_005163.2
(AKT1):c.49G>
A (p.Glu17Lys)
NP_001014432
E17K
Substitution Activation rs121434592 Heterozygous VCV000013983.2
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attributable to known preexistent periodontal disease. The gingivostomatitis and painful
dentition both resolved after a week of supportive treatment. Monthly blood biomarkers
(see Methods; Supplements 2a and 2b) changed little in his nearly 1 yr of treatment. His he-
moglobin was mildly low pretreatment and remainedmildly low or normal during treatment.
Serum bicarbonate was two units above the reference range on one occasion and one unit
above on another. The only trends we noted were that of a slightly declining alkaline phos-
phatase (slope=−0.09 r2 = 0.784, P<0.0001) and a slightly rising fasting glucose (slope=
0.001, r2 = 0.49, P=0.0037) and total cholesterol (slope=0.0007, r2 = 0.48, P=0.0044), al-
though it is important to note that all three of these remainedwell within their normal ranges.
ECG and echocardiogram at baseline and after 12 mo on miransertib 25 mg/m2/day were
normal. There was a 14%–17% reduction in absolute area of the CCTN of the soles after
12 mo of treatment (Fig. 1). Subjectively, the patient and his family have noted reduction
in the volume of a lipomatous overgrowth of the right lower abdominal wall, and greater mo-
bility and comfort of joints of the arms and hands. There was either improvement or stability
in all indices of general mood and well-being assessed by questionnaire (Supplements 3–5).
A repeat MRI scan 11 mo after commencement of treatment showed no obvious increase in
the size of overgrown soft tissue and bone of the right frontal region or lipomatous over-
growth in the right abdominal wall (Fig. 2).
DISCUSSION
This rare syndrome was first described in the modern medical literature in 1976 (Temtamy
and Rogers 1976) and given its name in 1983 (Wiedemann et al. 1983) to reflect the many
forms adopted by a Greek sea god: Overgrowth can affect any area of the body, and the dis-
order is highly phenotypically heterogeneous (Biesecker and Sapp 1993). The overgrowth in
Figure 1. Areas of cerebriform lesion on soles before (A,C ) and at follow-up after 12 mo treatment with mir-
ansertib 50 mg (25 mg/m2) per day (B,D), for right (A,B) and left (C,D) sole. Underneath the photographs are
calculated areas of the lesion on each sole (see Methods).
Treatment of Proteus syndrome with miransertib
C O L D S P R I N G H A R B O R
Molecular Case Studies
Biesecker et al. 2020 Cold Spring Harb Mol Case Stud 6: a004549 4 of 9
PS is associated with an activation of the AKT1 protein (Lindhurst et al. 2011). This name de-
rives from the AKR laboratory mouse (Furth 1978), which commonly had spontaneous leuke-
mia and tumors including thymomas, cells from one of which were found to harbor a
retrovirus designated AKT8 (Staal et al. 1977). The provirus sequence included part of a
Figure 2. RepresentativeMRI photographs frombefore treatment and after 11mo treatment. (A) Sagittal brain
T1MRI from baseline (left) and after 11 mo (right) showing no obvious progression of skull deformity or new le-
sion. (B) Axial T2 abdominal fat–saturatedMRI frombaseline (left) and after 11months (right) showing dilatation
of inferior vena cava (∗) and renal veins. (C ) Baseline abdominal wall axial T1 fat saturation MRI scan showing
lipomatous overgrowth (∗) of the right anterior abdominal wall. (D) After 11 mo treatment, abdominal wall axial
T1 fat saturation MRI scan showing width of lipomatous overgrowth (∗) of the right anterior abdominal wall.
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mouse host oncogene called v-akt, and in humans an orthologous sequence was identified
in a gene named AKT1, which was found to be amplified in gastric adenocarcinomas (Staal
1987). AKT1 is mutated in a number of human tumors (COSMIC database), and in essentially
all reports, the variant is the same as the variant that is found in themosaic state in individuals
with PS. This variant causes ligand-independent activation of the AKT1 signal, downstream
from tyrosine kinase growth factor receptors in the AKT/PIK3CA/mTOR pathway (Carpten
et al. 2007). Miransertib is an allosteric inhibitor of AKT1 that has been shown in vitro to reg-
ulate the growth of tumors that have this variant. It has also been shown to inhibit AKT1 sig-
naling in cells from patients with PS and a phase 0/1 pharmacodynamic study has shown an
acceptable adverse effects profile and some preliminary data for efficacy. Based on these
data and given the serious medical issues in this patient, compassionate use was considered
to be appropriate.
His initial dose was about 5 mg/m2/day, similar to the dosing of the NIH study (Keppler-
Noreuil et al. 2019). This was escalated to 15 mg/m2/day and then 25 mg/m2/day, as he had
no recognizable adverse effects other than a dry mouth that appeared on the lower doses
and persisted throughout treatment. There were transient gingivostomatitis and loose, pain-
ful teeth, which appeared to resolve spontaneously; viral studies were not performed. In the
lower-dose NIH study, grade 1 mucositis (CTCAE criteria) was observed four times (Keppler-
Noreuil et al. 2019). Wemonitored a number of clinical laboratory values for adverse effects,
none significantly changed from normal to abnormal. There were some subtle trends of glu-
cose, cholesterol, and alkaline phosphatase that were statistically significant, but are of un-
certain clinical significance. One grade 1 hyperglycemia was observed in the NIH study. In
contrast to the slight decline in alkaline phosphatase observed in this young man, there
was a single occurrence of grade 2 elevation in the NIH study. Therewas a single observation
of grade 1 cholesterol elevation in the NIH study. All three of these parameters remained
within normal ranges in the subject of this report. His D-dimer levels were abnormal before
treatment and remained abnormal.
We evaluated the individual for signs of the apparent benefit of treatment. The area of
the CCTN lesion of the foot was decreased, which is consistent with the results shown in
the phase 0/1 pharmacodynamic trial (Keppler-Noreuil et al. 2019). The radiologist did
not appreciate any enlargement of any of the overgrowth that was evaluable on the pre-
and post-treatment MRI scans. The foster parents believed that the lipomas had decreased
in volume. There was either improvement or stability in all indices of general mood and well-
being assessed by the questionnaire.
The rarity and slow rate of progression of PS pose considerable challenges to the design
of studies to measure the efficacy of any treatment. Long-term clinical trials, with novel study
designs, will need to be undertaken to assess the benefits and adverse effects of chronic
treatment. Until such trials can be completed, small studies and anecdotal reports of treated
individuals are useful to begin to understand the risks and benefits of primary treatment of
this disease. The results we report here are consistent with some evidence of benefit and
modest apparent adverse effects. As in any other report of anecdotal data, caution must
be exercised in interpreting the data, but in individuals such as the young man reported
here, we conclude that the compassionate use was appropriate and we are continuing his
treatment based on the assessment by his care providers and foster parents of the risks
and benefits of this experimental treatment at the 25 mg/m2/day dosing level.
METHODS
Baseline whole-body MRI, full blood count, clotting studies with D-dimers, liver function
tests, urea electrolytes creatinine, calcium magnesium phosphate, glucose, HbA1C, lipids,
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urinalysis, ECG, and echocardiogram were performed at baseline within a month before the
commencement of treatment, and selected blood tests were repeated monthly. The pa-
tient’s family was given a comprehensive list of side effects previously reported with miran-
sertib and asked to report on the appearance of any of these (or other) symptoms.
Whole-body MRI was repeated 1 yr after commencement of treatment and analyzed un-
blinded by a radiologist for apparent changes in deformity and overgrowth. Two-dimension-
al photographs available for the cerebriform lesions on the soles before treatment and after
12 mo of treatment (Fig. 1) were analyzed by Dermapix software (www.quantificare.com).
This quantified the area of the sole covered by the lesion (Fig. 1). The Self-reported Pain
Intensity Index (Melzack 1987; Cohen et al. 2008a,b), Impact of Pediatric Illness Scale-
Adult (Wolters et al. 2010, 2013, 2015; Martin et al. 2016), and Adult Pain Interference
Index form (Wicksell et al. 2009; Martin et al. 2015) were collated with parental question-
naires and were analyzed for marked or progressive changes without statistical analysis.
ADDITIONAL INFORMATION
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